Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab Plus Platinum Chemotherapy in Advanced NSCLC Post-Immunotherapy
NCT03904108Phase 2Terminated
- Start
- Jun 2019
- Primary completion
- Jul 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab in non-small cell lung cancer (NSCLC). Primary endpoints: Objective Response Rate at 12 months and Treatment Related Dose Delay or Treatment Discontinuation at 12 months. Started Jun 2019; status: terminated.
02
Drugs
ramucirumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03904108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03904108.